MMR/MSI in small intestine cancer

1 EU-approved indication in small intestine cancer needs a MMR/MSI result: pembrolizumab (2nd line, advanced).

Line of therapy

Approved indications, Small intestine cancer
DrugBiomarker requirementRegimenSettingConditions
dMMR / MSI-H1
Monotherapy
2L
advanced
Disease progression on or following at least one prior therapy

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Pembrolizumab (Keytruda)
    unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.